Taika Capital’s Novo Nordisk NVO Stock Holding History

Taika Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,200	Closed	-$952K	–	61
2023 Q4	$952K	Buy	+9,200	New	+$910K	0.55%	38

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Taika Capital's NVO Position: Q1 2024 in Review

Taika Capital sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 9,200 shares — an estimated $952K sold.

Taika Capital first reported a position in NVO in Q4 2023 and held it in 1 quarter. The position peaked at $952K in Q4 2023. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

Taika Capital reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
Taika Capital sold 9,200 Novo Nordisk shares in Q1 2024, an estimated $952K.
Taika Capital first reported a position in Novo Nordisk in Q4 2023 and held it in 1 quarter.
Taika Capital's Novo Nordisk position peaked at $952K in Q4 2023.
1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Taika Capital's 13F filing for Q1 2024, filed 15 May 2024.